BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A
Executive Summary
Although small patient base offers modest revenue opportunity, the Nulibry approval enables BridgeBio to get commercial operations underway.
You may also be interested in...
EU Accelerated Assessment Tracker
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to investigational products from Roche and CSL Behring/UniQure.
Accelerated Assessment Success In EU For CSL Behring And Roche
There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted.
Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities
Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.